Original article : Formulary selection criteria for biosimilars: Considerations for us health-system pharmacists

Hospital Pharmacy

Volumn 49, Issue 9, 2014, Pages 813-825

  Griffith, Niesha ^a   Mcbride, Ali ^b   Stevenson, James ^c   Green, Larry ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d AMGEN INC   (United States)

Author keywords

biologics; biosimilars; formulary; pharmacovigilance; reference product

Indexed keywords

BIOSIMILAR AGENT;

ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG LABELING; DRUG PACKAGING; DRUG SAFETY; DRUG STORAGE; EUROPEAN UNION; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; IMMUNOGENICITY; PATIENT EDUCATION; PATIENT SELECTION; PHARMACIST; PRACTICE GUIDELINE; UNITED STATES;

EID: 84914147035     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4909-813     Document Type: Article

References (48)

1. European Medicines Agency. European public assessment reports: Biosimilars. http://www.ema.europa.eu/ema/index.jsp? curl=pages%2Fmedicines%2Flanding%2Fepar-search.jsp& murl=menus%2Fmedicines%2Fmedicines.jsp&mid=WC0b 01ac058001d124&searchTab=searchByAuthType&already Loaded=true&isNewQuery=true&status=Authorised&s tatus=Withdrawn&status=Suspended&status=Refused& keyword=Enter+keywords&searchType=name&taxonomyPa th=&treeNumber=&searchGenericType=biosimilars&generic sKeywordSearch=Submit. Accessed October 21, 2013.
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19(3):411-419.
3. Gitter DM. Informed by the European Union experience: What the United States can anticipate and learn from the European Union's regulatory approach to biosimilars. Seton Hall Law Rev. 2011;41(2):559-592.
4. Biologics Price Competition and Innovation Act of 2009. http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/UCM216146.pdf. Accessed October 21, 2013.
5. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: Regulatory, scientifi c, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9(Suppl 4):S1-S22.
6. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: Considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053-1058.
7. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant. 2006;21(Suppl 5):v13-16.
8. Casadevall N, Edwards IR, Felix T, et al. Pharmacovigilance and biosimilars: Considerations, needs, and challenges. Expert Opin Biol Ther. 2013;13(7):1039-1047.
9. Griffith N, Green L. Formulary selection criteria for biosimilars in the United States: Focus on safety, effi cacy, and manufacturer capabilities. Presented at: International Pharmaceutical Federation (FIP) Centennial Congress of Pharmacy and Pharmaceutical Sciences, October 3-8, 2012; Amsterdam, Netherlands.
10. US Food and Drug Administration. Guidance for Industry: Scientifi c Considerations in Demonstrating Biosimilarity to a Reference Product. Rockville, MD: Author; 2012.
11. US Food and Drug Administration. Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Rockville, MD: Author; 2012.
12. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-388.
13. Zuniga L, Calvo B. Biosimilars: Pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf. 2010;19(7):661-669.
14. US Food and Drug Administration. Guidance for Industry: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Rockville, MD: Author; 2012.
15. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Official Journal of the European Union. 2001;311:67-128.
16. Directive 2004/27/EC of the European Parliament and the Council of 31 March 2004 amending directive 2001/83/EC on the community code relating to medicinal products for human use. Official Journal of the European Union. 2004;136:34-57.
17. European Medicines Agency. Guideline on Similar Biological Medicinal Products. London, UK: Author; 2005. CHMP/437/04.
18. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins As Active Substance: Non-Clinical and Clinical Issues. London, UK: Author; February 22, 2006. EMEA/ CHMP/BMWP/42832/2005.
19. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins As Active Substance: Quality Issues. London, UK: Author; February 22, 2006. EMEA/CHMP/BWP/49348/2005.
20. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies: Non-Clinical and Clinical Issues. London, UK: Author; May 30, 2012. EMA/CHMP/BMWP/403543/2010.
21. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies [draft]. London, UK: Author; November 18, 2010. EMA/ CHMP/BMWP/403543/2010.
22. IMS Health. Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape. http://www.imshealth.com/ims/Global/Content/Home%20 Page%20Content/IMS%20News/Biosimilars-Whitepaper. pdf. Accessed October 21, 2013.
23. US Food and Drug Administration. FDA approves new treatment for severe neutropenia in certain cancer patients. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm317392.htm. Accessed August 16, 2013.
24. Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28(2):386-393.
25. Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. 2013;69(4):929-936.
26. US Food and Drug Administration. Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Rockville, MD: Author; 2005.
27. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67(6):2346-2353.
28. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80(1):88-92.
29. de Erenchun FR. Evolving regulatory landscape for SBPs (biosimilars) in Asia. http://www.apec-Ahc.org/fi les/tp201105/ Fermin-Ruiz-de-Erenchun-27-April-Plenary-Session-4pm-[Revised].pdf. Accessed August 16, 2013.
30. Haag-Weber M, Eckardt KU, Horl WH, et al. Safety, immunogenicity and effi cacy of subcutaneous biosimilar epoetin-Alpha (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, double-blind study. Clin Nephrol. 2012;77(1):8-17.
31. Krämer I, Tredree R, Vulto AG. Points to consider in the evaluation of biopharmaceuticals. In: Schellekens H, Vulto AG, eds. Biopharmaceuticals for European Hospital Pharmacists. Mol, Belgium: Pharma Publishing & Media Europe; 2012:48-56.
32. Mica A, Green L. Drug availability: Considerations for the hospital pharmacist. Presented at: 17th Congress of the European Association of Hospital Pharmacists; March 21-23, 2012; Milan, Italy.
33. American Society of Health-System Pharmacists. Drug shortages: Current drugs. http://www.ashp.org/menu/Drug-Shortages/CurrentShortages. Accessed August 16, 2013.
34. Chabner BA. Drug shortages-A critical challenge for the generic-drug market. N Engl J Med. 2011;365(23):2147-2149.
35. Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653-1655.
36. Langleben D. A collaborative approach to reducing drug shortages. May/June, 2012. Hospital Pharmacy Europe Web site. www.hospitalpharmacyeurope.com/diane-langleben/ collaborative-Approach-reducing-drug-shortages.
37. McBride A, Holle LM, Westendorf C, et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm. 2013;70(7):609-617.
38. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther. 2013;93(2):170-176.
39. US Food and Drug Administration. Counterfeit version of Avastin in U.S. distribution. http://www.fda.gov/Drugs/Drug-Safety/ucm291960.htm. Accessed August 16, 2013.
40. Gray T, Bertch K, Galt K, et al. Guidelines for therapeutic interchange-2004. Pharmacotherapy. 2005;25(11):1666-1680.
41. Minghetti P, Rocco P, Cilurzo F, Vecchio LD, Locatelli F. The regulatory framework of biosimilars in the European Union. Drug Discov Today. 2012;17(1-2):63-70.
42. Minghetti P, Rocco P, Del Vecchio L, Locatelli F. Biosimilars and regulatory authorities. Nephron Clin Pract. 2011;117(1):c1-7.
43. Poon EG, Keohane CA, Yoon CS, et al. Effect of bar-code technology on the safety of medication administration. N Engl J Med. 2010;362(18):1698-1707.
44. Grabowski H, Cockburn I, Long G. The market for follow-on biologics: How will it evolve? Health Aff (Millwood). 2006;25(5):1291-1301.
45. Federal Trade Commission. Emerging health care issues: Follow-on biologic drug competition. www.ftc.gov/os/2009/06/ P083901biologicsreport.pdf. Accessed October 18, 2013.
46. Congressional Budget Office Cost Estimate: S. 1695 Biologics Price Competition and Innovation Act of 2007. Washington, DC: June 25, 2007.
47. Bourgoin AF. What you need to know about the follow-on biologic market in the US: Implications, strategies and impact. Thomson Reuters Healthcare & Science Regional Offices. http://thomsonreuters.com/content/science/pdf/ls/newportbiologics. pdf. Accessed August 16, 2013.
48. US Food and Drug Administration. CDER therapeutic biologic products. http://www.fda.gov/downloads/ForIndustry/ UserFees/PrescriptionDrugUserFee/UCM164641.pdf. Accessed August 16, 2013.